Organogenesis Holdings (2PQ) AI Stock Analysis

Organogenesis Holdings

(Frankfurt:2PQ)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Cash GenerationPositive operating and free cash flow provide internal funding capacity despite the reported net loss. If maintained, this cash generation can support operations, reduce reliance on external financing, and give management flexibility while the business works through its recovery and cost restructuring.

Negative Factors

Severe Revenue DeclineThe sharply reduced outlook indicates that the current demand and market reset is more severe than previously expected. Such a large revenue contraction threatens scale, weakens fixed-cost absorption, and makes a durable return to profitability dependent on successful recovery in core product volumes.

Organogenesis Holdings (2PQ) vs. iShares MSCI Germany ETF (EWG)

Market Cap: EUR 98.83M
Dividend Yield: ―
Average Volume (3M): ―
Price to Earnings (P/E): -0.9
Beta (1Y): 0.75
Revenue Growth: -0.68%
EPS Growth: -556.62%
Country: Germany
Employees: 854
Sector: Healthcare
Sector Strength: 51
Industry: Drug Manufacturers - Specialty & Generic

Organogenesis Holdings Business Overview & Revenue Model

Company Description

Organogenesis Holdings Inc. is a U.S.-based regenerative medicine firm that specializes in creating, producing, and marketing innovative therapies for advanced wound management, as well as surgical and sports medicine applications. Within its advance...

Organogenesis Holdings Earnings Call Summary

Earnings Call Date:Aug 05, 2026(Q2-2026)|% Change Since:-66.42%|Next Earnings Date:Nov 04, 2026

Earnings Call SentimentNegative

The call presented meaningful operational and clinical positives — sequential revenue recovery, strong clinical trial results (PuraPly AM and Affinity), FDA acceptance of the Amnuvx BLA and tangible cost-reduction measures — but these are outweighed by significant near-term financial stress: severe year-over-year revenue declines (≈58%), large operating and GAAP net losses, a halved cash position since year-end, lowered full-year revenue guidance, and deferred product launch timing to preserve cash. Management is focused on evidence-driven market share gains and expects improving adjusted EBITDA by Q4, but the company remains in a substantial recovery phase with execution and financing risks in the near term.

Positive Updates

Sequential Revenue and Volume Recovery

Net product revenue increased 18% quarter-over-quarter in Q2; Advanced Wound Care sales rose 23% sequentially and wound care unit volume grew 30% Q/Q, indicating measured improvement from Q1 trough.

Negative Updates

Severe Year-over-Year Revenue Decline

Net product revenue was $42.8 million in Q2, down 58% year-over-year; Advanced Wound Care revenue was $36.1 million, down 61% YoY; Surgical & Sports Medicine revenue was $6.7 million, down 18% YoY.

Company Guidance

Organogenesis updated 2026 guidance calling for total net revenue of $179M–$215M (a 62%–68% YoY decline) — with Advanced Wound Care sales of $151M–$183M, Surgical & Sports Medicine $26M–$30M and $1.9M of grant income — and expects sequential improvement in Q3 and Q4 but a second‑half YoY revenue decline of roughly 64%–74%. Management expects improving adjusted EBITDA quarter‑to‑quarter, targeting nearly a 60% reduction in adjusted EBITDA loss in 2H vs 1H at the low end and >90% reduction at the high end (including positive adjusted EBITDA in Q4); it plans to cut operating expenses (ex‑COGS) ~32% YoY in 2026 and >40% YoY in 2H. Cost actions include a June workforce reduction of 138 employees (≈$18M annualized savings), March and June restructurings together expected to reduce annual operating expenses by >$32M, estimated 3Q/4Q savings of ~$7M and ~$9M respectively; cash was $46.8M at 6/30/26 with no debt, an ATM facility up to $75M, and management believes cash plus product cash flows will fund operations for at least the next 12 months.

Organogenesis Holdings Risk Analysis

Organogenesis Holdings disclosed 73 risk factors in its most recent earnings report. Organogenesis Holdings reported the most risks in the "Finance & Corporate" category.

Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

2 New Risks

1.Our ability to comply with financial covenants under our credit agreement and raise capital may be materially adversely impacted by COVID-19.Q3, 2020

2.We are dependent on the proper functioning of our and third-party manufacturing facilities, our supply chain and our sales force, all of which could be negatively impacted by the global COVID-19 pandemic in a manner that could materially adversely affect our business, financial condition or results of operations.Q3, 2020

Organogenesis Holdings Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

DE:2PQ against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
PCRX	62Neutral	$1.45B	103.35	2.13%	―	5.71%	―
LFCR	60Neutral	$242.60M	-5.82	-376.95%	―	―	―
DERM	53Neutral	$145.92M	-22.89	-20.23%	―	20.89%	40.71%
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
EOLS	50Neutral	$485.47M	-14.19	123.11%	―	13.87%	45.83%
SNOA	42Neutral	$5.27M	-0.90	-53.56%	―	47.00%	50.49%

* Healthcare Sector Average

Performance Comparison

DE:2PQ and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
DE:2PQ	Organogenesis Holdings	0.69	-2.75	-80.09%
LFCR	Lifecore Biomedical, Inc.	6.40	-0.71	-9.99%
SNOA	Sonoma Pharmaceuticals, Inc.	1.10	-2.68	-70.90%
PCRX	Pacira	36.39	14.20	63.99%
EOLS	Evolus, Inc.	7.35	0.96	15.02%
DERM	Journey Medical Corporation	5.17	-3.35	-39.32%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Organogenesis Holdings AI Stock Analysis